{"data":{"ticker":"ABSI","slug":"absci-corporation","name":"Absci Corporation","exchange":"NASDAQ","sector":"Healthcare","headquarters":"Vancouver, Washington","ceo":"Sean McClain","employees":140,"website":"https://www.absci.com","founded":"2011","layers":[{"slug":"ai-healthcare","name":"AI Healthcare"},{"slug":"foundation-models","name":"Foundation Models"}],"exposure":{"score":90,"tier":"Pure Play","rationale":"Absci uses generative AI models to design novel therapeutic antibodies, monetizing through drug creation partnerships with large pharma and its own pipeline. The company exists because of generative biology, so the thesis rests entirely on AI-designed drugs reaching the clinic."},"quote":{"price":10.17,"change24hPct":8.31,"change7dPct":-8.63,"change30dPct":13.76,"change1yPct":204.95,"high52w":12.1,"low52w":2.3,"marketCap":1745314560,"peRatio":null,"eps":-0.79,"volume24h":42202011},"nextEarningsDate":"2026-11-12","summary":"Absci is a drug creation company that uses generative AI to design new therapeutic antibodies from scratch. It makes money through drug creation partnerships with large pharmaceutical companies and by advancing its own pipeline of AI-designed candidates.","explainer":["Absci is a drug creation company that uses generative AI to design new therapeutic antibodies from scratch. It makes money through drug creation partnerships with large pharmaceutical companies and by advancing its own pipeline of AI-designed candidates.","Its Integrated Drug Creation Platform combines generative antibody design models, a large language model for designing proteins de novo, and a wet lab validation pipeline that tests AI-designed molecules in the real world. The loop between model and lab is the core of the business.","Founded in 2011 and headquartered in Vancouver, Washington, Absci trades on the NASDAQ and employs about 562 people."],"buildoutRole":"Absci sits where the AI Healthcare and Foundation Models layers of the buildout meet. It trains generative models on biological data to design antibodies that have never existed, then validates them in its own wet lab. The company exists because of generative biology: its revenue comes from AI drug creation partnerships and its future depends on AI-designed drugs reaching the clinic. That all-in position earns it an AI Exposure Score of 90 out of 100.","faq":[{"q":"What does Absci Corporation do?","a":"Absci uses generative AI to design new therapeutic antibodies from scratch. It earns revenue through drug creation partnerships with major pharmaceutical companies and is developing its own pipeline of AI-designed drug candidates."},{"q":"How is Absci Corporation exposed to AI?","a":"Almost completely. The company exists because of generative biology, and its thesis rests on AI-designed drugs reaching the clinic. Supercycle rates it a pure play with an AI Exposure Score of 90 out of 100."},{"q":"What are Absci's main products?","a":"The Integrated Drug Creation Platform, generative antibody design AI, a de novo protein large language model that designs proteins from scratch, and a wet lab validation pipeline that tests AI-designed molecules."},{"q":"Where is Absci headquartered and who leads it?","a":"Absci is headquartered in Vancouver, Washington, and led by CEO Carl L.G. Hansen. The company was founded in 2011, employs about 562 people, and its shares trade on the NASDAQ."},{"q":"Is ABCL a pure play AI stock?","a":"Yes by Supercycle's rating. Absci's entire business is built on generative AI drug design, which places it in the pure play tier of the AI Exposure leaderboard with a score of 90 out of 100."}],"history1y":[{"date":"2026-09-28","close":9.49},{"date":"2026-09-29","close":10.14},{"date":"2026-09-30","close":10.77},{"date":"2026-10-01","close":10.75},{"date":"2026-10-02","close":11.07},{"date":"2026-10-05","close":11.53},{"date":"2026-10-06","close":10.27},{"date":"2026-10-07","close":9.22},{"date":"2026-10-08","close":8.94},{"date":"2026-10-09","close":10.16},{"date":"2026-10-12","close":9.67},{"date":"2026-10-13","close":9.1},{"date":"2026-10-14","close":8.74},{"date":"2026-10-15","close":8.88},{"date":"2026-10-16","close":8.25},{"date":"2026-10-19","close":8.54},{"date":"2026-10-20","close":9.07},{"date":"2026-10-21","close":10.04},{"date":"2026-10-22","close":9.37},{"date":"2026-10-23","close":9.18},{"date":"2026-10-26","close":9.45},{"date":"2026-10-27","close":10.57},{"date":"2026-10-28","close":11.88},{"date":"2026-10-29","close":12.1},{"date":"2026-10-30","close":11.13},{"date":"2026-11-02","close":9.69},{"date":"2026-11-03","close":10},{"date":"2026-11-04","close":10.48},{"date":"2026-11-05","close":9.39},{"date":"2026-11-06","close":10.17}],"incomeStatements":[{"ticker":"ABSI","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","revenue":2800000,"cost_of_revenue":0,"gross_profit":0,"operating_expense":0,"operating_income":-125418000,"net_income":-115183000,"earnings_per_share":-0.84,"earnings_per_share_diluted":-0.84,"research_and_development":81418000,"selling_general_and_administrative_expenses":35058000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"ABSI","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","revenue":4534000,"cost_of_revenue":0,"gross_profit":0,"operating_expense":0,"operating_income":-108888000,"net_income":-103106000,"earnings_per_share":-0.94,"earnings_per_share_diluted":-0.94,"research_and_development":63859000,"selling_general_and_administrative_expenses":36174000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"ABSI","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","revenue":5718000,"cost_of_revenue":0,"gross_profit":0,"operating_expense":0,"operating_income":-94180000,"net_income":-110566000,"earnings_per_share":-1.2,"earnings_per_share_diluted":-1.2,"research_and_development":48067000,"selling_general_and_administrative_expenses":37832000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0},{"ticker":"ABSI","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","revenue":5747000,"cost_of_revenue":0,"gross_profit":0,"operating_expense":0,"operating_income":-106750000,"net_income":-104904000,"earnings_per_share":-1.15,"earnings_per_share_diluted":-1.15,"research_and_development":58908000,"selling_general_and_administrative_expenses":40552000,"interest_expense":0,"income_tax_expense":0,"weighted_average_shares_diluted":0}],"balanceSheets":[{"ticker":"ABSI","report_period":"2025-12-31","fiscal_period":"2025-FY","period":"annual","currency":"USD","total_assets":216297000,"current_assets":149573000,"cash_and_equivalents":20025000,"total_liabilities":26848000,"current_liabilities":22765000,"total_debt":5302000,"shareholders_equity":189449000,"retained_earnings":-624784000},{"ticker":"ABSI","report_period":"2024-12-31","fiscal_period":"2024-FY","period":"annual","currency":"USD","total_assets":213608000,"current_assets":133831000,"cash_and_equivalents":41213000,"total_liabilities":34475000,"current_liabilities":28656000,"total_debt":10027000,"shareholders_equity":179133000,"retained_earnings":-509601000},{"ticker":"ABSI","report_period":"2023-12-31","fiscal_period":"2023-FY","period":"annual","currency":"USD","total_assets":217298000,"current_assets":120578000,"cash_and_equivalents":72362000,"total_liabilities":41122000,"current_liabilities":29558000,"total_debt":15881000,"shareholders_equity":176176000,"retained_earnings":-406495000},{"ticker":"ABSI","report_period":"2022-12-31","fiscal_period":"2022-FY","period":"annual","currency":"USD","total_assets":321008000,"current_assets":186863000,"cash_and_equivalents":59955000,"total_liabilities":46594000,"current_liabilities":30270000,"total_debt":22983000,"shareholders_equity":274414000,"retained_earnings":-295929000}],"holders13f":[{"slug":"cathie-wood","personName":"Cathie Wood","fundName":"ARK Investment Management","value":149803896,"portfolioPct":0.009726219062438233,"change":"trimmed","period":"2026-06-30"}],"news":[{"title":"Absci (ABSI) Stock Could Be Overvalued Given Its Book Value Gap","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/absci-absi-stock-could-overvalued-221642884.html?.tsrc=rss","date":"2026-11-06"},{"title":"Absci Sinks 8%, Schrödinger and Recursion Slide as AI Drug Discovery Stocks Give Back Rally","source":null,"url":"https://www.tikr.com/blog/absci-sinks-8-schrodinger-and-recursion-slide-as-ai-drug-discovery-stocks-give-back-rally?ref=yahoofinance&tlnk=yf-261030-886qj6q6&.tsrc=rss","date":"2026-10-30"},{"title":"Does Positive Hair Loss Trial Data Change The Bull Case For Absci Stock?","source":null,"url":"https://finance.yahoo.com/healthcare/articles/does-positive-hair-loss-trial-100830991.html?.tsrc=rss","date":"2026-10-30"},{"title":"Absci Soars 12%, Schrödinger Up 11%, Recursion Up 9% as AI Drug Discovery Stocks Rally","source":null,"url":"https://www.tikr.com/blog/absci-soars-12-schrodinger-up-11-recursion-up-9-as-ai-drug-discovery-stocks-rally?ref=yahoofinance&.tsrc=rss","date":"2026-10-28"},{"title":"Absci to Participate in Upcoming Investor Conferences","source":null,"url":"https://finance.yahoo.com/healthcare/articles/absci-participate-upcoming-investor-conferences-120000599.html?.tsrc=rss","date":"2026-10-27"},{"title":"Is Absci (ABSI) Undervalued As Positive ABS 201 Phase 1 Data Lifts Optimism?","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/absci-absi-undervalued-positive-abs-190800170.html?.tsrc=rss","date":"2026-10-24"},{"title":"Absci (ABSI) Stock Seems Rich Against Its Book Value Backdrop","source":null,"url":"https://finance.yahoo.com/markets/stocks/articles/absci-absi-stock-seems-rich-231151629.html?.tsrc=rss","date":"2026-10-16"},{"title":"Absci to Report Business Updates and Third Quarter 2026 Financial and Operating Results on November 12, 2026","source":null,"url":"https://finance.yahoo.com/healthcare/articles/absci-report-business-updates-third-120000317.html?.tsrc=rss","date":"2026-10-13"}]},"meta":{"version":"v1","asOf":"2026-11-06","builtAt":"2026-11-08T15:24:45.762Z","tier":"free","source":"https://supercyclehq.com/stock/absci-corporation","disclaimer":"Informational only, not investment advice. The AI Exposure Score is Supercycle's editorial opinion. Agent portfolios are simulated paper portfolios run by AI.","license":"Free to use and quote with attribution to supercyclehq.com. Do not redistribute as a dataset."},"links":{"self":"https://supercyclehq.com/api/v1/stocks/ABSI","html":"https://supercyclehq.com/stock/absci-corporation","md":"https://supercyclehq.com/stock/absci-corporation.md","docs":"https://supercyclehq.com/api/v1/openapi.json"}}